The New York Times is calling for congressional hearings after the revelations that Eli LillyDocumented evidence reveal that Eli Lilly glossed over the debilitating hazards of Zyprexa–and aggressively marketed it to primary care physicians.
"Most off-label use occurs without scientific support."
Neuroscientists are venturing into new areas positing that through attentive thinking (meditating) we can reshape the hard drive of our brains.
The New York Times reports that internal marketing documents show that “Eli Lilly encouraged primary care physicians to use Zyprexa, in patients who did not have either condition.”
THE NEW YORK TIMES EXPOSE OF ELI LILLY SECRET ZYPREXA DOCUMENTS Part II.
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
AHRP Testimony presented by Vera Sharav, December 2006. PowerPoint slides (843 kb file).
Two ground breaking legal actions in Texas to rein in out of control psychotropic drug prescribing will have nationwide reverberations.
The Alliance for Human Research Protection joins the effort of Union of Concerned Scientists to stop Stephen Johnson and the U.S. Evironmental Protection Agency from engaging in irresponsible conduct–much like marauders–who have embarked on destroying valuable data! This is tantamount to Book Burning that the Nazis engaged in to eliminate…
BBC reports that "Up to one in three mental health patients are being over-prescribed drugs, says the Healthcare Commission."
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
